FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983005864> ?p ?o ?g. }

• W2983005864 endingPage "799" @default.
• W2983005864 startingPage "791" @default.
• W2983005864 abstract "The present study aims to investigate retrospectively the efficacy and safety of sorafenib combined with radiofrequency ablation (RFA) to treat unresectable remnant large hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The 229 consecutive patients with unresectable remnant large HCC (diameter ≥ 5 cm) received RFA and sorafenib (RFA + Sor group, n = 102) or sorafenib (Sor group, n = 127) from January 2010 to January 2016. Complications and overall survival (OS) of the two groups were compared and subgroup analysis carried out. Survival curves were drawn using the Kaplan-Meier method. The RFA + Sor group had no additional serious adverse events. The average OS was 18.3 ± 1.6 months (95% confidence interval [CI]: 15.2-21.4) in the RFA + Sor group and 14.1 ± 1.1 months (95% CI: 11.8-16.3) in the Sor group, a difference the log-rank test indicated was significant (P = 0.03). The 1-, 2- and 3-year survival rates of the RFA + Sor group were 56.9%, 34.3%, and 11.7%, and those of the Sor group were 42.5%, 22.0%, and 5.5%, respectively. The between-group differences in 1- and 2-year survival rates were statistically significant, but not the difference in 3-year survival rates. Subgroup analysis showed that the RFA + Sor group achieved significantly more lifetime benefits than the Sor group in: patients with tumors 5-10 cm in diameter (hazard ratio [HR] 0.42, 95% CI 0.21-1.06 vs. HR 0.94, 95% CI 0.63-1.22); patients with an isolated tumor (HR 0.36, 95% CI 0.19-0.81 vs. HR 0.93, 95% CI 0.55-1.24); and patients with remnant lesion volume < 50% after TACE (HR 0.47, 95% CI 0.21-1.12 vs. HR 0.77, 95% CI 0.46-0.81). RFA with sorafenib is safe and effective for unresectable remnant large HCC, controlling tumor progression and prolonging survival better than sorafenib alone." @default.
• W2983005864 created "2019-11-22" @default.
• W2983005864 creator A5022526821 @default.
• W2983005864 creator A5032877694 @default.
• W2983005864 creator A5046489971 @default.
• W2983005864 creator A5054561588 @default.
• W2983005864 creator A5080332738 @default.
• W2983005864 date "2019-01-01" @default.
• W2983005864 modified "2023-10-18" @default.
• W2983005864 title "Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone." @default.
• W2983005864 cites W1949921930 @default.
• W2983005864 cites W1969947714 @default.
• W2983005864 cites W1981198531 @default.
• W2983005864 cites W2007454701 @default.
• W2983005864 cites W2023530235 @default.
• W2983005864 cites W2027604117 @default.
• W2983005864 cites W2029055742 @default.
• W2983005864 cites W2033073518 @default.
• W2983005864 cites W2034361058 @default.
• W2983005864 cites W2068451863 @default.
• W2983005864 cites W2093986504 @default.
• W2983005864 cites W2113464761 @default.
• W2983005864 cites W2117067620 @default.
• W2983005864 cites W2128985765 @default.
• W2983005864 cites W2143270463 @default.
• W2983005864 cites W2319133637 @default.
• W2983005864 cites W2324407602 @default.
• W2983005864 cites W2342513208 @default.
• W2983005864 cites W2403335287 @default.
• W2983005864 cites W2413016863 @default.
• W2983005864 cites W2558644206 @default.
• W2983005864 cites W2626765824 @default.
• W2983005864 cites W2684250302 @default.
• W2983005864 cites W2727497670 @default.
• W2983005864 cites W2802633445 @default.
• W2983005864 cites W2803637437 @default.
• W2983005864 cites W2888698090 @default.
• W2983005864 cites W3151288436 @default.
• W2983005864 cites W360836421 @default.
• W2983005864 cites W2591655368 @default.
• W2983005864 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6511642" @default.
• W2983005864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31106004" @default.
• W2983005864 hasPublicationYear "2019" @default.
• W2983005864 type Work @default.
• W2983005864 sameAs 2983005864 @default.
• W2983005864 citedByCount "5" @default.
• W2983005864 countsByYear W29830058642019 @default.
• W2983005864 countsByYear W29830058642020 @default.
• W2983005864 countsByYear W29830058642022 @default.
• W2983005864 crossrefType "journal-article" @default.
• W2983005864 hasAuthorship W2983005864A5022526821 @default.
• W2983005864 hasAuthorship W2983005864A5032877694 @default.
• W2983005864 hasAuthorship W2983005864A5046489971 @default.
• W2983005864 hasAuthorship W2983005864A5054561588 @default.
• W2983005864 hasAuthorship W2983005864A5080332738 @default.
• W2983005864 hasConcept C126322002 @default.
• W2983005864 hasConcept C126894567 @default.
• W2983005864 hasConcept C187960798 @default.
• W2983005864 hasConcept C197934379 @default.
• W2983005864 hasConcept C207103383 @default.
• W2983005864 hasConcept C2777377203 @default.
• W2983005864 hasConcept C2777546739 @default.
• W2983005864 hasConcept C2778019345 @default.
• W2983005864 hasConcept C2778455285 @default.
• W2983005864 hasConcept C2778695046 @default.
• W2983005864 hasConcept C2778902805 @default.
• W2983005864 hasConcept C3019894029 @default.
• W2983005864 hasConcept C44249647 @default.
• W2983005864 hasConcept C71924100 @default.
• W2983005864 hasConcept C90924648 @default.
• W2983005864 hasConceptScore W2983005864C126322002 @default.
• W2983005864 hasConceptScore W2983005864C126894567 @default.
• W2983005864 hasConceptScore W2983005864C187960798 @default.
• W2983005864 hasConceptScore W2983005864C197934379 @default.
• W2983005864 hasConceptScore W2983005864C207103383 @default.
• W2983005864 hasConceptScore W2983005864C2777377203 @default.
• W2983005864 hasConceptScore W2983005864C2777546739 @default.
• W2983005864 hasConceptScore W2983005864C2778019345 @default.
• W2983005864 hasConceptScore W2983005864C2778455285 @default.
• W2983005864 hasConceptScore W2983005864C2778695046 @default.
• W2983005864 hasConceptScore W2983005864C2778902805 @default.
• W2983005864 hasConceptScore W2983005864C3019894029 @default.
• W2983005864 hasConceptScore W2983005864C44249647 @default.
• W2983005864 hasConceptScore W2983005864C71924100 @default.
• W2983005864 hasConceptScore W2983005864C90924648 @default.
• W2983005864 hasIssue "4" @default.
• W2983005864 hasLocation W29830058641 @default.
• W2983005864 hasOpenAccess W2983005864 @default.
• W2983005864 hasPrimaryLocation W29830058641 @default.
• W2983005864 hasRelatedWork W1972665675 @default.
• W2983005864 hasRelatedWork W2096388013 @default.
• W2983005864 hasRelatedWork W2370121646 @default.
• W2983005864 hasRelatedWork W2754556903 @default.
• W2983005864 hasRelatedWork W2782366082 @default.
• W2983005864 hasRelatedWork W2785875853 @default.
• W2983005864 hasRelatedWork W2983005864 @default.
• W2983005864 hasRelatedWork W3031610734 @default.
• W2983005864 hasRelatedWork W3202428687 @default.

• next